Free tool
FAERS Monitor: Neupro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021829 or its brand name (Neupro, Rotigotine). Reports on generic versions are filed under their own applications.
Reports
14,738
Serious
9,295
63% of reports
Hospitalization
4,277
Death reported
2,175
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product adhesion issue1,963
- drug ineffective1,171
- fall1,013
- death984
- off label use922
- parkinson^s disease800
- hallucination771
- dyskinesia698
- tremor655
- nausea555
- dizziness523
- somnolence477
- fatigue469
- gait disturbance466
- insomnia466
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 128 |
| 2008 | 603 |
| 2009 | 126 |
| 2010 | 131 |
| 2011 | 129 |
| 2012 | 170 |
| 2013 | 260 |
| 2014 | 302 |
| 2015 | 471 |
| 2016 | 820 |
| 2017 | 917 |
| 2018 | 866 |
| 2019 | 1,295 |
| 2020 | 1,207 |
| 2021 | 1,579 |
| 2022 | 1,461 |
| 2023 | 1,098 |
| 2024 | 1,164 |
| 2025 | 1,075 |
| 2026 | 936 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,421 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product adhesion issueSignal | 1,963 | 82.9 | 79.4 | 150,293 |
| dyskinesiaSignal | 698 | 24.9 | 23.2 | 15,759 |
| hallucinationSignal | 771 | 14.7 | 13.8 | 9,795 |
| tremorSignal | 655 | 5.7 | 5.2 | 2,512 |
| fallSignal | 1,013 | 4.4 | 4.1 | 2,648 |
| gait disturbanceSignal | 466 | 3.5 | 3.2 | 827 |
| somnolenceSignal | 477 | 3.4 | 3.1 | 806 |
| insomniaSignal | 466 | 2.5 | 2.3 | 422 |
| death | 984 | 1.6 | 1.5 | 249 |
| off label use | 922 | 1.5 | 1.4 | 161 |
| dizziness | 523 | 1.5 | 1.4 | 88 |
| drug ineffective | 1,171 | 1.3 | 1.2 | 71 |
| nausea | 555 | 1.0 | 0.9 | 0 |
| fatigue | 469 | 0.9 | 0.8 | 11 |
| parkinson^s disease | 800 | 0.0 | 0.0 | 1,140,665 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.